Shire Viropharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

VPHM 0.0000
price chart
Shire Buys ViroPharma for $4.2 Billion
LONDON— Shire SHPG 1.04 % PLC has agreed to buy ViroPharma Inc. for $4.2 billion, extending its bet on the market for medicines treating rare diseases.
Shire to Acquire ViroPharma
Shire to Acquire ViroPharma in Strategic Move to Strengthen Rare Disease ...  MarketWatch
Related articles »  
$4.2 billion deal gives ViroPharma execs huge paydays
Shire's $4.2 billion acquisition of ViroPharma last month generated a huge payday for ViroPharma's top executives and board members.
Inside the deal: Shire's $4.2B acquisition of ViroPharma
While a half-dozen companies kicked ViroPharma's tires this summer, only one ended up making an offer to buy the company.
Making Sense of the Drama About ViroPharma
Of the four main HAE medications, only Dyax's Kalbitor and Shire's Firazyr can be administered subcutaneously for patients over 16 and 18 years old, respectively.
Related articles »  
ViroPharma surges, Shire settles as investors digest $4.2 billion merger
The 25% boost in ViroPharma Inc. 's share price stayed steady but support for Shire plc started to slide toward the breakeven point in Monday morning trades as investors digested the prospects of a merger between the two biotechnology companies.
Shire nears completion of $4.2B ViroPharma deal
U.S.-traded shares of Shire fell 2.5 percent, or $3.72, to $146.24 in morning trading Friday, while broader trading indexes dropped about 1 percent.
Related articles »  
Shire waives condition for ViroPharma acquisition
Shire said Wednesday it has waived the Office of Fair Trading approval condition that was part of its previously announced $50 per share tender offer for all of the outstanding shares of ViroPharma Inc. The London-based Office of Fair Trading [OFT] is ...
Related articles »  
ViroPharma Said to Hire Goldman Amid Sanofi Interest
Sept. 13 (Bloomberg) -- ViroPharma Inc., a producer of drugs that treat rare diseases, has attracted interest from suitors including European drugmakers Sanofi and Shire Plc, said people with knowledge of the process. ViroPharma's shares surged.
Viropharma Explores Possible Sale After Unsolicited Offer, Shares Soar  ValueWalk
ViroPharma Skyrockets on Buyout Rumors
Related articles »  
Shire extends tender offer for ViroPharma stock
Shire has extended its previously announced tender offer for all of the outstanding common shares of ViroPharma until midnight on Jan. 9. All of the other terms and conditions of the $50 per share tender offer remain unchanged.
Related articles »  
Company Shares of Shire plc Drops by -1.21%
Shire plc (NASDAQ:SHPG) has lost 1.21% during the past week and dropped 2.17% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 0.03%.